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Abstract 
The preS antigen of hepatitis B virus (HBV) corresponds to the N-terminal polypeptide in the 
large (L) antigen in addition to the small (S) antigen. The virus-like particle (VLP) of the S 
antigen is widely used as a vaccine to protect the population from HBV infection. The presence 
of the S antigen and its antibodies in patient blood has been used as markers to monitor 
hepatitis B. However, there is very limited knowledge about the preS antigen. We generated a 
preS VLP that is formed by a chimeric protein between preS and hemagglutinin (HA), and the 
matrix protein M1 of influenza virus. The HBV preS antigen is displayed on the surface of preS 
VLP. Asn112 and Ser98 of preS in VLP were found to be glycosylated and O-glycosylation of 
Ser98 has not been reported previously. The preS VLP shows a significantly higher 
immunogenicity than recombinant preS, eliciting robust anti-preS neutralizing antibodies. In 
addition, preS VLP is also capable of stimulating preS-specific CD8+ and CD4+ T cell responses 
in Balb/c mice and HBV transgenic mice. Furthermore, preS VLP immunization provided 
protection against hydrodynamic transfection of HBV DNA in mice. The data clearly suggest that 
this novel preS VLP could elicit robust immune responses to the HBV antigen, and can be 
potentially developed into prophylactic and therapeutic vaccines.  
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1. Introduction 
Under the current immunization and antiviral programs, hepatitis B virus (HBV) infection 
remains a major global public health problem. Approximately 2 billion people have been infected 
worldwide during their lifetime, and more than 350 million are chronic carriers of the virus. HBV 
infection may cause acute and chronic hepatitis, which leads to liver cirrhosis (LC) and 
hepatocellular carcinoma (HCC). Current HBV vaccines on the market are based on the virus-
like particle (VLP) of the S antigen, and effectively prevent most people from acquiring HBV 
infection. However, almost 5-10% people vaccinated with the available vaccines fail to mount an 
adequate antibody response to offer protection. As an additional antigen on infectious HBV 
particles, preS could also provide B and T cell epitopes which may promote the humoral and 
cellular responses and enhance the seroprotection rate by overcoming non-responsiveness to 
the S antigen-only vaccines (4). 
There are three envelope proteins in the HBV virion, S, M and L. The preS protein is part 
of the L protein, a 163 amino acid extension at the N-terminus of the S protein (genotype A). 
preS may be further divided as preS1 (a.a.1-108) and preS2 (a.a.109-163). In the M protein, 
only preS2 is present at the N-terminus in addition to the amino acids that are common among 
the S, M and L proteins. Two well-known functions are related to preS. First of all, preS includes 
the region that interacts with the specific host receptor (2). Previous studies have mapped the 
interaction motif to be within the first 48 amino acids of preS (3). The other important function of 
preS is that in the preS region, there are highly immunogenic sites as B and T cell epitopes. It 
has been reported that preS could induce humoral responses in mice which were 
nonresponsive to the S antigen, indicating that preS represents a potential antigen for novel 
HBV vaccine candidates (4). Notably, humoral response may play a major role in preventing 
HBV spreading to uninfected cells. In addition, it is generally believed that a proper CD4+ helper 
T cell response is a prerequisite for an adequate humoral response. Furthermore, T cell 
responses may help extend the longevity of humoral immunity. However, how these preS 
epitopes are related to virus clearance is not very clear. It is widely accepted that the CD8+ T 
cell response is primarily responsible for HBV clearance in both cytopathic and noncytopathic 
manner, and the HBV-specific CD8+ T cells are able to clear HBV from infected hepatocytes by 
secretion of antiviral cytokines, such as IFN-γ, and TNF-α.  
     VLPs resemble authentic native viruses in structure and morphology, but are non-
infectious, because they assemble without containing the genetic material (1). Compared to 
individual proteins or peptides, VLPs significantly improve humoral responses by presenting 
conformational epitopes more similarly as the native virus. Owing to their highly repetitive 
surface, VLPs are capable of eliciting robust B cell responses in the absence of adjuvants by 
efficiently cross-linking specific receptors on B cells. Besides, VLPs could also induce potent 
cytotoxic T lymphocyte (CTL) responses in immunized animals.  
      In this study, we have designed a preS VLP that consists of influenza M1 protein and the 
transmembrane domain and cytoplasmic tail of influenza hemagglutinin (HA) as the scaffold. 
The HBV preS antigen is displayed on the surface of VLP when it is fused with the HA fragment. 
We assessed the immunogenicity of preS VLP in mice. Here we report that immunization with 
preS VLP induced both potent humoral and cellular immune responses in Balb/c mice and HBV 
transgenic mice, and protected mice from hydrodynamic transfection of HBV DNA, indicating its 
potential as an effective prophylactic vaccine candidate or a potential therapeutic vaccine 
against HBV infection.  
 
2. Materials and methods 
Materials and methods are provided in the Supporting Information.  
 
3. Results  
3.1 Construction and preparation of preS VLP  
Co-expression of influenza virus M1 and HA releases a VLP decorated with HA antigen 
(11). In order to generate a VLP that is decorated with HBV preS antigen, we constructed a 
chimeric protein that has the preS sequence fused at the N-terminus of a HA fragment that 
includes its transmembrane domain and the cytoplasmic tail (Fig. 1A). The signal peptide from 
HA was also added in front of the preS sequence which may be removed after the chimeric 
protein is expressed. The amino acid 41 of M1 was mutated to Ala to enhance the release of the 
VLP (12). After transfection of 293T cells with pCAGGS-M1, pCAGGS-preS-HA, or both plasmids, 
respectively, total RNAs were extracted and analysed for the transcription levels of M1 and 
preS-HA. The qRT-PCR results suggested that both M1 and preS-HA genes had been 
transcribed adequately in 293T cells 48 h after transfection (Fig. 1B). After co-transfection of 
pCAGGS-M1 and pCAGGS-preS-HA into 293T cells, expression of the preS antigen was 
readily detected by immunofluorescent microscopy (Fig. 1C and 1D). If the M1 protein was not 
co-expressed, the preS-HA chimeric protein appeared to be unable to expose the preS antigen 
on the exterior of the cellular membrane because the preS antigen was only detectable after the 
cellular membrane was permeabilized with Triton X-100 (Fig. 1C and 1D).  
There has been an interesting observation of L antigen topology (13-15). It was found that 
the preS region of the L antigen may be at both the side of cytosol or the side of lumen of ER 
membrane (13). The association of the preS region with the S region in the L antigen is critical to 
the preS topology of the L antigen (14). In our construct of VLP, the S region of the L antigen is 
not present and the N-terminus of preS may not be myristoylated. preS in the chimeric protein is 
completely in the cytosol side when preS-HA is expressed alone. In co-expression, M1 allows 
preS to be presented on the exterior of the cytoplasmic membrane, likely through its interactions 
with the cytoplasmic tail of HA. In addition, M1 also plays the critical role of assembly and 
budding of VLP (see below). 
3.2 Purification and characterization of preS VLP 
Next, we set out to purify the preS VLP from supernatant of the transfected 293T cells. 
Recombinant preS was also produced in E. coli (5) (Fig. S1) and was used to generate specific 
polyclonal antibodies. The culture media were collected from the cells 72 h post-cotransfection 
of pCAGGS-M1 and pCAGGS-preS-HA. The culture media were laid on a sucrose gradient and 
subjected to ultracentrifugation. A sample was collected from each of the 30%, 40% or 50% 
sucrose fractions. By SDS-PAGE and western blot analysis, the protein corresponding to the 
preS-HA antigen was identified (Fig.  2A and 2B). Based on western blot analysis, the secreted 
preS-HA spans a region of much larger molecular weight than the calculated molecular weight 
of the preS-HA chimeric protein. We concluded that the secreted forms of preS-HA are 
glycosylated, consistent with previous reports of the L antigen (16-18). A band consistent with the 
molecular weight (27.8 kDa) of M1 was shown in Fig. 2A. This could account for the appearance 
of an unstained region (about 27.8 kDa) in western blot due to that M1 occupies the position 
(Fig. 2B and 2C). The sample was further characterized by liquid chromatograph-mass 
spectrometer/mass spectrometer (LC-MS/MS). The M1 sequence identified by MS analysis 
covered above 90% of the full length M1 sequence (Fig. S2). A negative stain electron 
micrograph showed that the sucrose fractions contain virus-like particles (Fig.  2E). These data 
showed that VLPs composed of M1 and preS-HA proteins were successfully made and purified. 
To map glycosylation sites, we used Peptide -N-Glycosidase F (PNGase F) and/or O-
Glycosidase to treat the 40% sucrose fraction, respectively. When preS VLP was treated with 
PNGase F to remove N-linked glycans, and O-Glycosidase to remove O-linked glycans, or both, 
a band with reduced molecular weight was observed (Fig. 2C). The molecular weight of the 
band is consistent with that of preS-HA. When O-Glycosidase was used alone, a smaller portion 
of deglycosylated preS-HA was observed. The remaining protein also seemed to have a lower 
molecular weight, suggesting that the majority of preS-HA in VLP was modified with both N-
linked and O-linked glycans. This is consistent with the pattern when both glycosidases were 
used to treat preS VLP. When PNGase F was used alone, on the other hand, a more significant 
amount of deglycosylated preS-HA was observed, suggesting a good portion of preS-HA in VLP 
contains only N-Linked glycans.  preS VLP was further characterized by LC-MS/MS and 
analysed by Byonic. Both preS-HA and M1 sequences identified by MS analysis covered above 
85% of the full length sequences (Fig. S2). Asn112 and Ser98 within the preS domain were 
predicted to be modified by N-glycan and O-glycan, respectively (Fig. 2D, and Table S1). N-
glycosylation of Asn4 and Asn112 has been reported previously.(18)  However, we did not 
identify peptides containing glycosylated Asn4, which may be due to the experimental condition 
of MS. Interestingly, O-glycosylation of Ser98 has not been reported previously, the 
physiological role of O-glycosylated Ser98 remains to be elucidated.  
3.3 preS VLP elicits robust neutralizing antibodies in Balb/c mice 
In order to investigate humoral immunogenicity of preS VLP, Balb/c mice were 
immunized each with 10 µg of preS VLP total protein, or recombinant preS (5) with alum adjuvant, 
respectively (Fig. 3A). PBS was used as a mock control. A booster was given on day 22.  Blood 
samples were collected from each mouse on day 52 and 112, and sera were prepared from 
these samples. All serum samples were diluted by various folds before the serum antibody titers 
were determined by ELISA (Fig. S5). The data revealed that preS VLP is more potent than 
recombinant preS protein in generating anti-preS antibodies, even without the use of any 
adjuvant (Fig. 3B-D). In particular, preS VLP elicited high level anti-preS total IgG including both 
anti-preS IgG1 (Th2 isotype) and IgG2a (Th1 isotype), indicating a balanced Th1/Th2 response 
against preS VLP. 
To further test whether anti-preS VLP sera could block HBV from infecting human 
hepatocytes, in vitro infection experiments were conducted. Using hepatitis B immunoglobulin 
(HBIG) as a positive control, the anti-preS VLP sera from three mice clearly prevented HBV 
from infecting HepG2/hNTCP cells, as demonstrated by a decreased level of HBeAg in the 
supernatant of cell culture (Fig. 3E). Collectively, these results indicate that preS VLP can 
stimulate anti-preS neutralizing antibodies in mice. 
3.4 preS VLP provokes strong T cell responses in Balb/c mice 
T cell responses play a vital role in the induction of humoral immunity, and are crucial to 
effectiveness of a therapeutic HBV vaccine (19, 20). To evaluate whether preS contained vital 
immunogenic epitopes to elicit strong T cell responses, we used preS VLP and preS protein to 
immunize Balb/c mice. Splenocytes were harvested and stimulated with preS-specific T cell 
peptides (Table 1) (21-23). After stimulation for 6 h, T cell responses were determined using flow 
cytometric analysis (FACS) and ELISPOT (Fig. 4). FACS data showed that mice immunized 
with preS VLP elicited a higher percentage of preS-specific IFN-γ-producing CD4+ and CD8+ T 
cells than either the controls or those immunized with recombinant preS protein (Fig. 4A, and 
4B). ELISPOT also demonstrated that preS-specific IFN-γ-producing T cells are more abundant 
in mice immunized with preS VLP than either the controls or those immunized with recombinant 
preS protein (Fig. 4C and 4D). Since IFN-γ-producing T cells play a key role in controlling and 
clearing HBV in infected individuals, our results implicate that preS VLP can evoke potent preS-
specific T cell responses that may be important in HBV clearance. 
3.5 preS VLP provides protection against hydrodynamic transfection of HBV DNA.   
To test whether preS VLP-induced T cell responses played a role in protection against 
HBV infection, mice immunized with preS VLP or preS protein were hydrodynamically 
transfected with HBV DNA on day 70 of post-immunization (Fig. 3A). HBV replication was 
induced by hydrodynamic injection of pHBV1.3 plasmid (10 μg/mouse) that contains a 1.3-fold-
overlength genome of HBV. Liver tissues were collected on day 77 for analysis of HBV RNA 
copies, viral antigen load, and humoral responses. HBV RNA copies from about 50 mg of each 
tissue sample were measured by qRT-PCR (Fig. 5A). The levels of HBV RNA in preS VLP-
immunized animals were lower than that in animals immunized with recombinant preS. Liver 
sections stained for HBV core antigen indicated that the HBcAg-positive hepatocytes were 
eliminated almost entirely in preS VLP-immunized animals, but persisted in preS-immunized 
animals (Fig. 5B). We also used ELISA assays to detect HBV proteins including HBsAg and 
HBeAg in the serum samples collected from each immunized mouse on day 0, 2, 4 and 7 after 
hydrodynamic transfection of HBV DNA. As shown in Fig. 5C, HBsAg levels in preS VLP-
immunized animals were nearly undetectable throughout 7 days, but rose to high levels in 
animals immunized with recombinant preS on day 4 after transfection. The serum levels of 
HBeAg also remained nearly undetectable in preS VLP-immunized animals over the course of 7 
days. On the other hand, HBeAg levels in preS-immunized animals elevated on day 4 then 
dropped to nearly undetectable levels on day 7 after transfection (Fig. 5D). This phase of 
HBsAg and HBeAg clearance coincides with the development of anti-preS neutralizing 
antibodies (Fig. 5E). In line with previous study (7), serum alanine aminotransferase (ALT) 
activity increased significantly on day 2, indicative of successful transfection (Fig. 5F). 
Subsequently, the ALT activity of all mice returned to baseline by day 7 after transfection, 
implying that preS VLP did not cause liver damage. This was further supported by H&E staining, 
which suggested that no obvious necroinflammatory lesions were observed in liver section of 
mice from preS VLP group on day 7 after transfection (Fig. S3). Collectively, preS VLP 
prophylactically protects mice against hydrodynamic transfection of HBV DNA. 
 
 
3.6 preS VLP immunization stimulates potent humoral and cellular responses in HBV transgenic 
mice 
We next set out to investigate the therapeutic potential of preS VLP immunization by 
employing HBV transgenic mice as a model of chronic infection. HBV transgenic mice were first 
primed with preS VLP or PBS, and then were boosted on days 22 and 43, respectively. Despite 
that HBV transgenic mice have become tolerance to HBV (24), preS VLP could still induce high 
levels of anti-preS total IgG including both anti-preS IgG1 (Th2 isotype) and IgG2a (Th1 isotype) 
(Fig. 6B-D), suggesting a balanced Th1/Th2 response against preS VLP. In addition, preS VLP 
immunization could stimulate a higher percentage of preS-specific IFN-γ-producing CD4+ and 
CD8+ T cells than the control by FACS analysis (Fig. 6E, and 6F). Furthermore, ELISPOT 
results also showed that preS-specific IFN-γ-producing T cells are more plentiful in mice 
immunized with preS VLP than the control (Fig. 6G and 6H), implying the therapeutic potential 
of preS VLP. Taken together, preS VLP vaccine could induce preS-specific CD8+ and CD4+ T 
cell responses in HBV transgenic mice. 
4. Discussion 
Previous studies of immune responses to the preS antigen, or preS1 and preS2, were 
largely carried out with recombinant proteins or synthetic peptides (26-32). These polypeptides do 
not have the folded structure or glycosylation of preS found in HBV particles. The full extent of 
immune responses to the preS antigen may not have been recapitulated by these reports. We 
have successfully developed a unique system to produce preS VLP. In contrast to recombinant 
preS, preS VLP is able to evoke much higher levels of neutralizing antibodies in Balb/c mice, 
even without any adjuvants. This is likely attributed to that preS VLPs display highly repetitive, 
glycosylated and folded preS antigen on the surface. Importantly, the sera from mice immunized 
with preS VLP is capable of blocking HBV from infecting HepG2/hNTCP cells in vitro. Moreover, 
the preS VLP could provide protection against HBV in the hydrodynamic transfection model. 
Anti-preS1 antibodies were previously found to be effective in neutralization of HBV (33). The 
identification of protective epitopes within the preS1 region reveals that preS1 specific 
antibodies neutralize the virus by blocking the binding of host NTCP receptor (2, 29). The potent 
antigenicity of preS VLP suggests that its preS antigen may have similar immunological 
properties of HBV particles. 
Therapeutic vaccination requires multiple T cell responses, especially the CD8+ T cell 
responses (19, 20). It is generally believed that immunization with a therapeutic vaccine would 
stimulate the immune system to elicit a specific CD8+ T cell response that is capable of 
controlling viral infection. In particular, therapeutic vaccination is fascinating for HBV because 
individuals who become chronically infected have a weak and narrowly focused CD8+ T cell 
response (34, 35). Compared to chronically infected individuals, there are greater numbers of 
HBV-specific IFN-γ secreting CD4+ and CD8+ T cells in individuals that resolve acute infections 
(36).  Indeed, preS VLP induce potent CD4+ and CD8+ T cell responses both in Balb/c mice and 
HBV transgenic mice. The T cell epitopes of preS used in this study clearly reactivated specific 
T cell responses. In addition, humoral immune responses could also be induced by preS VLP in 
HBV transgenic mice. These findings suggest that preS VLP may have the therapeutic potential 
for chronic HBV infection.  
Interestingly, the preS domain of VLP was identified to be N-glycosylated at Asn112 and 
O-glycosylated at Ser98. O-glycosylation of Ser98 has not been reported previously. Alignment 
of the primary sequences of preS from all HBV genotypes revealed that this residue is highly 
conserved except that a threonine is at position 98 in genotype E HBV preS (Fig. S4). Notably, 
the N-glycosylation of preS is crucial for secretion and stability of preS antigen (37). The 
physiological role of O-glycosylation of Ser98 and relationship between glycosylation and 
immunogenicity await further studies.  
Due to the additional B and T cell epitopes in HBV preS region, preS represents an 
attractive antigen for HBV vaccine candidates that are able to overcome non-responsiveness to 
the S antigen-based vaccines, or break immune tolerance in patients with chronic HBV 
infections (4, 38). Previous clinical trials have shown that vaccines containing preS/S are effective 
and even superior to traditional S protein containing vaccine (39-42). This may be due to the 
stimulation of preS-specific antibodies; however, the role of anti-preS antibodies was not 
evaluated in these studies. On the other hand, such epitopes may contribute to the better 
immunogenicity of these vaccines, although T cell immune responses induced by specific T cell 
epitopes from preS have not been defined.  
The preS antigen has been exploited previously as candidates of prophylactic or 
therapeutic vaccines. When recombinant preS proteins were used in immunization, the antibody 
titers were not very high (43). The ability of neutralizing HBV by these antibodies is limited. More 
critically, no T cell responses against HBV were demonstrated (44, 45). This is consistent with that 
isolated proteins generally do not induce T cell responses because they usually are not 
internalized by antigen presenting cells (46). In order to overcome the barrier, virus or yeast 
vectors were employed to express HBV antigens (47, 48). However, there are safety concerns 
when a replicating vector is used despite their capability to induce strong T cell responses. In 
addition, these vectors may only be given once because the host will establish immunity against 
the vector. A recent study showed that administration of preS-based allergen-derived peptides 
with Alum adjuvant induced preS-specific antibodies that inhibit hepatitis B infection in vitro (27). 
However, the stability of this peptide vaccine may be the limitation for clinical use. Furthermore, 
the preS in this peptide vaccine may not adopt a similar conformation as preS in HBV particles. 
Our design of preS VLP has the advantages of mimicking a virus particle and being able to 
interact with the antigen presenting cells to elicit both CD4+ and CD8+ T cell responses, and at 
the same time, it permits multiple doses and does not replicate any foreign microorganisms. In 
summary, preS VLP represents an effective vaccine candidate for prophylactic protection and 
potential therapeutic intervention against HBV infection.  
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Table 1. preS-specific T cell epitopes. 
Epitope Residues Amino acid sequence Reference 
1 preS1 10-19 PLGFFPDHQL (50) 
2 preS1 41-56 WPAANQVGVGAFGPGL (21) 
3 preS2 109-134 MQWNSTAFHQALQDPR
VRGLYLPAGG 
(22) 
 
Figure legends 
Fig. 1. Construction and production of preS VLP. (A) Schematic representation of pCAGGS-preS-HA 
and pCAGGS-M1 used for preS VLP production, and pET28b-preS used for the expression of 
recombinant preS antigen. (B)  qRT-PCR analysis was used to confirm the transcription of preS-HA and 
M1. (C, D) Immunofluorescent imaging of preS-HA expressing cells. (C) 293T cells were transfected with 
mock control, pCAGGS-M1, pCAGGS-preS-HA, or both plasmids. Cells were not permeabilized with 
Triton X-100 before staining. The nuclei were stained with DAPI (blue), and the preS antigen was stained 
with purified polyclonal rabbit anti-preS antibody, detected with Alexa Fluor® 488-Conjugated goat anti-
rabbit secondary antibody. (D) The cells were the same as those in panel C, except that the cells were 
permeabilized with Triton X-100 before staining.  
Fig. 2. Characterization of preS VLP. (A) SDS-PAGE analysis of fractions from sucrose gradient 
centrifugation. The major protein component is in the 40% sucrose fraction. The position of M1 is 
indicated by the arrow. (B) Western blot analysis with purified polyclonal rabbit anti-preS antibody. Lanes 
1 and 2 showed the presence of the preS-HA antigen in fractions from sucrose gradient centrifugation. 
The unstained region corresponds to M1. (C) The sample in 40% sucrose fraction was treated with 
Peptide -N-Glycosidase F (PNGase F) and/or O-Glycosidase, and the preS antigen was detected by 
western blot. (D) Identification of glycosylated sites in preS-HA. The preS domain in preS-HA is colored 
black. Glycosylated residues identified in this study are underlined. Glycosylated residues which have 
been reported previously are indicated by dots(18). (E) An electron micrograph showing preS virus-like 
particles (preS VLP). Magnification, 11,000 ×.  
Fig. 3. preS VLP elicits superior neutralizing antibodies compared to recombinant preS 
vaccination. Balb/c mice were immunized intramuscularly with preS VLP (n=6), recombinant preS 
protein (n=6), or PBS (n=6). (A) Time schedule for preS VLP vaccination to prevent hydrodynamic 
transfection of HBV DNA. (B-D) The serum anti-preS titers were determined by ELISA. The plates were 
coated with 1 μg/mL purified recombinant preS. The immunization condition is labeled next to chart color 
codes. The sera were diluted by 100 folds in all the assays. (E) Neutralization of HBV infectivity in 
HepG2/hNTCP cells by mouse anti-preS VLP sera or hepatitis B immunoglobulin (HBIG) (0.144 mg/mL). 
The mouse anti-preS VLP sera were diluted by various folds. HBeAg values at one week post infection 
were measured using an ELISA kit. The data are represented as mean ± SEM.  
Fig. 4. preS VLP induces stronger T cell responses than recombinant preS vaccination. Balb/c mice 
were immunized intramuscularly with preS VLP (n=6), recombinant preS protein (n=6), or PBS (n=6). 30 
days postimmunization, splenocytes were isolated and analyzed for CD8, CD4, and IFN-γ expression by 
flow cytometry (A-B). CD8+ T cells (A) or CD4+ T cells (B) were gated, and IFN-γ-producing cells are 
presented as the percent average from each group. (C) Splenocytes were isolated and analyzed for IFN-γ 
expression using an IFN-γ ELISPOT assay. ELISPOT experiments were performed in triplicate wells per 
condition. (D) Representative images of ELISPOT from each group are shown. All values are presented 
as the average from each group, and error bars indicate ± SEM. Pool, indicates the mixture of peptide 10, 
41 and 109, and preS indicates recombinant preS protein. 
Fig. 5. Immunization with preS VLP offers protection against hydrodynamic transfection of HBV 
DNA. Balb/c mice were immunized intramuscularly with preS VLP (n=6), recombinant preS protein (n=6), 
or PBS (n=6). On day 70, HBV replication was induced by hydrodynamic injection of pT-HBV1.3 plasmid 
via tail vein (10 μg per mouse). (A) Liver-associated HBV RNA copies were measured by qRT-PCR. (B) 
Immunohistochemistry analysis of liver tissues. Quantifications represent average numbers of HBcAg-
positive cells per 100× field (n = 3 with 5 fields counted per sample). Representative images are shown. 
Magnification, 100×. Serum analysis for HBsAg (C), HBeAg (D) and anti-preS antibody titers (E) was 
completed by ELISA on days 0, 2, 4, and 7 post transfection. (F) Serum alanine aminotransferase (ALT) 
activity was determined with a Hitachi 7600 Automatic Biochemistry Analyzer. All values are presented as 
the average from each group, and error bars indicate ± SEM. 
Fig. 6. Immunization with preS VLP induces robust anti-preS antibodies and T cell responses in 
HBV transgenic mice. HBV transgenic mice were immunized intramuscularly with preS VLP (n=6) or 
PBS (n=6). (A) Time schedule for preS VLP as a vaccine to treat HBV transgenic mice. (B-D) The serum 
anti-preS titers were determined by ELISA. The plates were coated with 1 μg/mL purified recombinant 
preS. The immunization condition is labeled next to chart color codes. The sera were diluted by 100 folds 
in all the assays. CD8+ T cells (E) or CD4+ T cells (F) were gated, and IFN-γ-producing cells are 
presented as the percent average from each group. (G) On day 70, splenocytes were isolated and 
analyzed for IFN-γ expression by ELISPOT assays. ELISPOT experiments were performed in triplicate 
wells per condition. (H) Representative images of ELISPOT from each group are shown. All values are 
presented as the average from each group, and error bars indicate ± SEM.  
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Supplementary Materials and Methods 
Plasmids and cells 
The vector for expressing HBV preS (adw subtype, Accession Number AGW20902) in 
E. coli (pET28b-preS) was constructed previously (5). The His-tagged preS protein 
was expressed and purified as described previously (5). Recombinant preS was 
quantitated by the bicinchoninic acid assay (BCA assay). To prepared polyclonal 
rabbit anti-preS antibody, purified recombinant preS protein was mixed with Alum 
adjuvant and injected subcutaneously into New Zealand rabbits four times in two 
months, and the antisera was collected from the rabbits two weeks postimmunization 
and was subjected to affinity chromatography. The plasmids for expressing M1 
protein (the matrix protein) of influenza virus A/sw/Spain/53207/04 and a preS-HA 
(HA=hemagglutinin) chimeric protein were constructed by inserting the coding 
sequence in pCAGGS. The amino acid 41 of M1 was mutated to Ala (pCAGGS-M1). 
The preS-HA has the sequence of HBV preS followed by aa521-566 of HA 
(pCAGGS-preS-HA). 293T cells were maintained in DMEM supplemented with 10% 
fetal bovine serum (Invitrogen). All the fetal bovine serum used in this study was 
inactivated at 56°C for 30 min. 
Preparation and characterization of the virus-like particles 
The pCAGGS-M1 and pCAGGS-preS-HA plasmids were transfected into 293T cells 
with polyethylenimine. 72 h after transfection, the culture medium was centrifuged at 
6,000 rpm for 15 min at 4°C to remove cellular debris, followed by centrifugation at 
22,000 rpm for 3 h at 4°C. The pellet was resuspended in PBS at 4°C overnight, and 
further purified through a 20%-60% sucrose gradient in a Beckman SW41Ti rotor at 
30,000 rpm for 3 h at 4°C. The 40% sucrose fraction was harvested and diluted with 
PBS by about 5 folds. After centrifugation at 22,000 rpm for 3 h at 4°C to remove the 
sucrose, the virus-like particles were resuspended in PBS at 4°C overnight. 
Quantitation of preS VLP total proteins was carried out by the bicinchoninic acid 
assay (BCA assay). A sample was applied to a 400mesh carbon-coated copper grid, 
and stained with 1% phosphotungstic acid (J&K Scientific). preS VLP was visualized 
on a Tecnai G2 Spirit transmission election microscope operating at 120 kV. 
Indirect immunofluorescence 
293T cells were grown on glass coverslips and transfected with pCAGGS-M1 and 
pCAGGS-preS-HA. 48 h posttransfection, cells were fixed with 4% paraformaldehyde. 
Cells were classified into two groups. One was permeabilized with 0.2% Triton X-100 
for 5 min, the other without permeabilization. After blocking for 1 h in PBS containing 5% 
goat serum, all cells were incubated with purified polyclonal rabbit anti-preS antibody 
at 4°C overnight. Cells were washed with PBS following incubation with Alexa Fluor® 
488-Conjugated goat anti-rabbit secondary antibody (ZSGB-BIO, Beijing, China) for 1 
h at 37°C. After washing, cells were stained with DAPI for 10 min, and then mounted 
onto microscope slides. Confocal slices were acquired with a 100× objective, using a 
Zeiss 510 confocal microscope with random sampling. 
Western blot analysis 
Western blot analysis was performed as described previously (6). Briefly, samples 
were mixed with 4 × SDS-PAGE loading buffer followed by heating at 95°C for 10 min. 
The denatured samples were separated by electrophoresis on 12%-SDS-PAGE gel 
and transferred to a PVDF membrane. After blocking with a 5 % (wt/vol) skim milk 
solution, the membrane was incubated with purified polyclonal rabbit anti-preS 
antibody (1:1,000) and then with HRP-conjugated goat anti-rabbit IgG antibody 
(Abclonal). The chemiluminescent detection reaction was performed and monitored 
by ChemiDoc XRS System (Bio-Rad). 
Glycosylation analysis 
The glycosylation of preS-HA in VLP was analysed by western blot and LC-MS/MS. 
For western blot analysis, the sample from 40% sucrose fraction was treated with 
PNGase F and/or O-Glycosidase (New England Biolabs) following the manufacturer’s 
instructions. Briefly, 2 μL of samples, 1 μL of Glycoprotein Denaturing Buffer (10×) 
and 7 μL of H2O were combined in a total reaction volume of 10 μL, and samples were 
denatured by heating the reaction mixture at 100°C for 10 min followed by cooling to 
room temperature. 2 μL of GlycoBuffer 2 (10×) and 2 μL of 10% NP-40, 2 μL of 
Neuraminidase (only used for O-Glycosidase), H2O, and 1 μL of O-Glycosidase 
and/or PNGase F were combined in a total reaction volume of 20 μL, followed by 
incubation at 37°C for 18 h. Samples were subsequently subjected to western blot 
analysis as described above. 
For LC-MS/MS analysis, the sample from 40% sucrose fraction was subjected to 
electrophoresis on a 12%-SDS-PAGE gel, which was stained by coomassie R250. 
The bands corresponding to 25-30 kDa were cut out, subjected to reduction with 10 
mM DTT at 56°C for 50 min, and subsequent alkylated with 55 mM iodoacetamide 
(IAA) for 30 min at room temperature in the dark. In-gel digestion was conducted with 
trypsin [Promega, enzyme: protein= 1:50 (wt/wt)] at 37°C for 16 h in 25 mM 
ammonium bicarbonate buffer, followed by lyophilization.  
The lyophilized samples were re-dissolved in 2% acetonitrile, 0.1% formic acid, and 
loaded on a ChromXP C18 (3 μm, 120 Å) nanoLC trap column. The inline trapping, 
desalting procedure was carried out at a flow rate of 2 μL/min for 10 min with 100% 
solvent A (Solvent A: water/acetonitrile/formic acid = 98/2/0.1% solvent B: 2/98/0.1%). 
A 60-min gradient elution ranging from 5-35% acetonitrile (0.1% formic acid) was 
carried out onto an analytical column (75 μm x 15 cm C18- 3μm 120 Å, ChromXP 
Eksigent). LC-MS/MS analysis was performed with a Triple TOF 5600 System (AB 
SCIEX, Concord, ON) fitted with a Nanospray III source (AB SCIEX, Concord, ON). 
Data were acquired using an ion spray voltage of 2.5 kV, curtain gas of 30 PSI, 
nebulizer gas of 5 PSI, and an interface heater temperature of 150 °C. The MS 
instrument was operated as TOF-MS scans. For IDA, survey scans were acquired in 
250 ms and as many as 25 product ion scans (90 ms) were collected if exceeding a 
threshold of 150 counts per second (counts/s) and with a +2 to +4 charge-state. A 
Rolling collision energy setting was applied to all precursor ions for collision-induced 
dissociation. Dynamic exclusion was set for ½ of peak width (~12 s).  
For glycosylation analysis, the raw files were searched against the local database 
including the protein sequences for M1, preS-HA and decoys, using Byonic (version 
2.11.0). All of the N-glycan and O-glycan databases were used for searching possible 
glycan modifications, with the following parameters: mass tolerances were 10 ppm 
and 40 ppm for the precursor and fragment ions, respectively; enzyme specificity was 
set as RK, with a maximum of two missed cleavages; carbamidomethylation of Cys 
residues were set as fixed modification (57.021464 Da); variable modifications 
including oxidation of Met residues, acetylation of protein N-terminals, and 
carbamidomethylation of N-terminal, His and Lys were allowed; the 1% False 
Discovery Rate Analysis was also engaged. Glycopeptides were filtered using the 
following criteria: Score≥300, Delta Mod≥10, |Log Probability|≥2. 
Immunization and hydrodynamic transfection in Balb/c mice 
All mouse experiments were conducted in accordance with the institutional guidelines 
following the experimental protocol reviewed and approved by the Institutional Animal 
Care and Use Committee of Peking University. Female Balb/c mice of 6-8 weeks old 
were immunized by injecting the antigen preparation in the hindlimb. A booster was 
given on day 22. Blood was collected on day 52 and 112, and neutralizing antibody 
titers were determined by ELISA. On day 52, activated T cells in splenocytes were 
analyzed by ELISPOT and flow cytometry (FACS). The immunized mice were 
hydrodynamically transfected on day 70. 10 μg of pHBV1.3, a plasmid containing 
1.3X genome length of HBV, genotype D, ayw subtype, was used in hydrodynamic 
injection to establish HBV replication as previously described (7). Blood samples were 
collected at different time points to measure HBV antigens. On day 77, mice were 
sacrificed and liver tissues were used for measuring antigens and RNA of HBV. 
HBV infection and neutralization assays 
Virus neutralization assays were conducted as described previously (8, 9). HepAD38 
cells were cultured in Dulbecco's modified Eagle's medium F12 (DMEM F12) 
(Invitrogen, Carlsbad, USA) containing 2 mM L-glutamine, 50 U/ml penicillin, and 10% 
fetal bovine serum (Invitrogen) at 37°C and 5% CO2. The virus-containing 
supernatant from HepAD38 culture was concentrated using Amicon Ultra-15 
centrifugal filters (Millipore, Billerica, USA). HBV titers were quantified using a 
qRT-PCR HBV DNA detection kit (Qiagen, Hilden, Germany) and expressed as 
genome equivalents (geq). For infection experiments, 5×105 HepG2/hNTCP cells per 
well were cultured in 24-well plate and incubated overnight with the viral inoculum 
(M.O.I. of 500) alone or together with various dilutions of mouse anti-preS VLP sera or 
1,000 fold dilution of hepatitis B immunoglobulin (HBIG) (from Chengdu Rongsheng 
Bioproduct Company, with a protein concentration of 144 mg/ml), with 4% PEG 
present during virus infection. Medium was changed every 2 or 3 days, and HBeAg 
was measured at 1 week post infection using Diagnostic ELISA Kit for Hepatitis B e 
antigen (Kehua Bio-engineering). 
Isolation of splenocytes  
For splenocyte isolation, splenocytes were gently grinded followed by passaging 
through 40 μm strainers and treating with ACK lysing buffer. After washing with PBS, 
cells were resuspended in DMEM supplemented with 10% fetal bovine serum 
(Invitrogen) and 1% Penicillin-Streptomycin–L-Glutamine.  
Enzyme-linked immunospot assay 
T cell responses were determined using an IFN-γ ELISPOT set (BD Biosciences) 
following the manufacturer’s protocol. Briefly, 96-well plates were coated with purified 
anti-mouse IFN-γ antibody (1:200) at 4°C overnight, and then were blocked for 2 h 
using DMEM supplemented with 10% fetal bovine serum (Invitrogen) and 1% 
Penicillin-Streptomycin– L-Glutamine. Splenocytes were seeded at 2×105/well. 
Peptides representing previously described epitopes present in preS (Table 1) or 
purified recombinant preS protein at a concentration of 20 μg/ml were used to 
stimulate cells for 36 h at 37°C in a 5% CO2 and humidified incubator, with media and 
phorbol myristate acetate (PMA)/ionomycin-treated cells used as negative and 
positive controls, respectively. After being washed, cells were incubated with 
biotinylated anti-mouse IFN-γ antibody (1:250) for 2 h at room temperature, and then 
incubated with streptavidin-horseradish peroxidase (HRP) (1:1,000) for 1 h. Following 
the final washes, 3-amino-9-ethylcarbazole (AEC) substrate (Alfa Aesar) was added 
to the wells and allowed to develop at room temperature for 25 to 35 min. The reaction 
was stopped with distilled water, and the plates were allowed to air dry before 
spot-forming cells were enumerated automatically with an ELISPOT plate reader.  
Flow cytometry 
Splenocytes were resuspended in DMEM supplemented with 10% fetal bovine serum 
(Invitrogen) and 1% Penicillin-Streptomycin– L-Glutamine, and then were seeded at 
2×106 /well. The cells were then stimulated for 6 h with preS-specific peptides or 
purified recombinant preS protein diluted to a final concentration of 10 μg/ml in DMEM 
supplemented with 2 μg/ml brefeldin A (BD Biosciences). The cells were then washed 
in staining buffer (PBS containing 2% fetal bovine serum) and stained for CD8 and 
CD4 surface expression for 30 min at 4°C using fluorescein isothiocyanate 
(FITC)-conjugated anti-mouse CD8 antibody (BD Biosciences) and peridinin 
chlorophyII protein(PerCP)-conjugated anti-mouse CD4 antibody (BD Biosciences). 
Then the cells were washed, fixed, and permeabilized using a commercially available 
Cytofix/Cytoperm kit (BD Biosciences). The cells were then stained for 30 min at 4°C 
for intracellular cytokine expression using phycoerythrin (PE)-conjugated anti-mouse 
IFN-γ antibody (BD Biosciences). After washing, cells were resuspended in staining 
buffer and analysed using a BD FACS CantoTM II flow cytometer (BD Biosciences) 
and FACSDiva Version 6.1.3. Results were generated from data gathered from 
200,000 cells. 
ELISA 
Purified recombinant preS antigen (1 µg/ml) was absorbed to 96 well plates, blocked 
with 10% BSA, and then 50 µl of 1:100 dilution of sera was added and incubated for 
30 min at 37°C. The plates were washed six times, and followed by incubation with a 
1:5,000 dilution of HRP-conjugated anti-mouse IgG, IgG1 (Santa Cruz Biotechnology) 
or IgG2a (BD Biosciences) for 30 min at 37°C. After washing, the plates were 
incubated with TMB substrate for 10 minutes before stopping with 2 M H2SO4. 
Absorbance at 450 nm was measured by the 2104 EnVision® Multilabel Reader 
(PerkinElmer). Endpoint dilutions were performed (Fig. S5). In addition, serum 
samples were diluted 1:5 for HBsAg ang HBeAg detection (Kehua Bio-engineering). 
ALT activity analysis 
The level of serum alanine aminotransferase (ALT) was measured with a Hitachi 7600 
Automatic Biochemistry Analyzer. 
RT-PCR and qRT-PCR analyses 
For detecting mRNA in 293T cells transfected with expression vectors, 48 h 
posttransfection, total RNAs from 293T cells were extracted using the QIAGEN 
RNeasy Mini Kit following the manufacturer’s instructions. Total RNAs were stored at 
-20°C until being used. Any possible contaminating DNA was digested by DNase I 
(Takara). Total RNAs were quantified using the NanoDrop 2000 spectrophotometer 
(Thermo Scientific). 1 μg total RNAs were reverse transcribed into cDNA using the 
PrimeScript RT Reagent Kit with gDNA Eraser (Takara) in a 20 μL reaction as 
described previously (10). cDNA derived from 5 ng total RNAs was used as template 
for qRT-PCR amplification. Primers (preS-HA-FW: 5’-CCACCAATCGGCAGTC-3’) 
and (preS-HA-RV: 5’-GCCACCAGCAGGAAGAT-3’) were used for preS-HA 
transcripts; (M1-FW: 5’-TGACAACAACCAACCCACT-3’) and (M1-RV: 
5’-CTGCTGCTTGCTCACTCG-3’) were for M1 transcripts; (β-actin-FW: 
5’-TCATGAAGTGTGACGTGGACATC-3’) and (β-actin-RV: 
5’-CAGGAGGAGCAATGATCTTGATCT-3’) were used for β-actin transcripts. 
qRT-PCR was performed with GoTaq qPCR Master Mix (Promega) following the 
manufacturer’s protocol for a total reaction volume of 20 μL in the CFX96 Real-Time 
PCR Detection System (Bio-Rad). The reaction product was subjected to agarose gel 
electrophoresis. 
For hydrodynamic transfection studies, total RNAs from the liver of 
HBV-transfected mice were isolated with Trizol reagent (Invitrogen) according to 
manufacturer’s manual. Any possible contaminating DNA was digested by DNase I 
(Takara). Total RNAs were quantified using the NanoDrop 2000 spectrophotometer 
(Thermo Scientific). 1 μg total RNAs were reverse transcribed into cDNA using the 
PrimeScript RT Reagent Kit with gDNA Eraser (Takara) in a 20 μL reaction as 
previously described(10). cDNA derived from 2 ng total RNAs was used as template for 
qRT-PCR amplification. Primers (HBV2270FW: 5’-GAGTGTGGATTCGCACTCC-3’) 
and (HBV2392RV: 5’-GAGGCGAGGGAGTTCTTCT-3’) were used for HBV RNA 
transcripts (2). qRT-PCR was conducted with GoTaq qPCR Master Mix (Promega) 
following the manufacturer’s instructions for a total reaction volume of 20 μL in the 
CFX96 Real-Time PCR Detection System (Bio-Rad). 
H&E staining and immunohistochemistry 
Liver tissues were collected and fixed in 10% neutral formalin (Sigma). After paraffin 
embedding, liver sections were stained with hematoxylin and eosin (H&E). 
Immunohistochemistry was performed using polyclonal rabbit anti-HBcAg antibody 
(Dako) to detect HBV core antigen. 
Immunization in HBV transgenic mice 
All mouse experiments were performed in accordance with the institutional guidelines 
following the experimental protocol reviewed and approved by the Institutional Animal 
Care and Use Committee of Peking University. Six- to 8-week-old female HBV 
transgenic mice (ayw subtype) were obtained from Infectious Disease Center of No. 
458 Hospital (Guangzhou, China). HBV transgenic mice were immunized 
intramuscularly with 20 μg of preS VLP in the hindlimb, and were boosted on days 22 
and 43, respectively. Blood was collected on days 0, 30 and 70, and anti-preS 
antibody titers were determined by ELISA. On day 70, activated T cells in splenocytes 
were analyzed by ELISPOT and flow cytometry.  
Statistical analysis 
The data are represented as mean ± SEM. The statistical difference was determined 
by a two-tailed Student’s t-test (*P<0.05; **P<0.01; ***P<0.001 vs. the mock group). 
 
 
Table S1: Identification of glycosylated residues of preS-HA. 
Peptide sequence Glycans 
|Log 
Prob| 
Score 
Delta 
Mod. 
Score 
R.DSHPQAMQWN[+1257.44941]S
TAFHQALQDPR.V 
HexNAc(3)Hex(4) 4.15 343 235.9 
R.QPTPIS[+406.15875]PPLR.D HexNAc(2) 6.66 528.6 92.2 
R.QPTPIS[+203.07937]PPLR.D HexNAc(1) 8.14 617 45.1 
R.QPTPIS[+963.31794]PPLR.D 
HexNAc(1)Hex(1)NeuGc(1
)NeuAc(1) 
4.98 354 39.3 
R.QPTPIS[+730.26439]PPLR.D HexNAc(2)Hex(2) 5.32 440.1 38.1 
R.QPTPIS[+947.32303]PPLR.D 
HexNAc(1)Hex(1)NeuAc(2
) 
7.32 514.1 38.1 
R.QPTPIS[+568.21157]PPLR.D HexNAc(2)Hex(1) 6.65 572.1 33.8 
R.QPTPIS[+365.13220]PPLR.D HexNAc(1)Hex(1) 8.14 619.8 32.4 
R.QPTPIS[+656.22761]PPLR.D 
HexNAc(1)Hex(1)NeuAc(1
) 
8.55 603.2 31.7 
R.QPTPIS[+859.30699]PPLR.D 
HexNAc(2)Hex(1)NeuAc(1
) 
4.43 421.9 24.1 
R.QSGRQPTPIS[+656.22761]PPL
R.D 
HexNAc(1)Hex(1)NeuAc(1
) 
5.12 466.8 17.2 
 
 Fig.S1: SDS-PAGE analysis of purified recombinant preS protein (A) and polyclonal 
rabbit anti-preS antibody (B).  
 
 
Fig.S2: LC-MS/MS identification of M1 and preS-HA in the sample from 40% sucrose 
fraction. The identified sequences are colored green. 
 
 
Fig.S3: Liver tissue sections of Balb/c mice from each group were stained with 
hematoxylin and eosin on day 7 after hydrodynamic transfection of HBV DNA. 
Magnification, 100×.  
 
 Fig.S4: Partial alignment of the primary sequences of preS from all HBV genotypes. 
preS in VLP is genotype A.  
 
 
 
Fig.S5: Measurement of anti-preS antibodies by endpoint dilution assay. The serum 
anti-preS titers were determined by ELISA. The plates were coated with 1 μg/mL purified 
recombinant preS. The sera were diluted by various folds. 






